Advanced lipoprotein analysis shows atherogenic lipid profile that improves after metreleptin in patients with lipodystrophy

AB Kinzer, RD Shamburek… - Journal of the …, 2019 - academic.oup.com
AB Kinzer, RD Shamburek, M Lightbourne, R Muniyappa, RJ Brown
Journal of the Endocrine Society, 2019academic.oup.com
Context Patients with lipodystrophy have dyslipidemia and insulin resistance. Leptin
treatment with metreleptin in lipodystrophy decreases insulin resistance and lowers
triglycerides without changing high-density lipoprotein. Detailed measurement of lipoprotein
particles with nuclear magnetic resonance (NMR) spectroscopy can offer insights into
cardiovascular disease (CVD) risk and lipid metabolism beyond a standard lipid panel. We
hypothesized that patients with lipodystrophy would have a more atherogenic lipid profile …
Context
Patients with lipodystrophy have dyslipidemia and insulin resistance. Leptin treatment with metreleptin in lipodystrophy decreases insulin resistance and lowers triglycerides without changing high-density lipoprotein. Detailed measurement of lipoprotein particles with nuclear magnetic resonance (NMR) spectroscopy can offer insights into cardiovascular disease (CVD) risk and lipid metabolism beyond a standard lipid panel. We hypothesized that patients with lipodystrophy would have a more atherogenic lipid profile than controls at baseline, which would be ameliorated with metreleptin treatment.
Objective
To characterize the lipoprotein profile in patients with lipodystrophy compared with controls and to evaluate effects of metreleptin treatment.
Design, Setting, Patients, and Intervention
Patients with lipodystrophy (N = 17) were studied before and after metreleptin for 2 weeks and 6 months and compared with 51 insulin-sensitive sex-matched controls.
Main Outcome Measures
Lipoprotein profiles were measured by NMR with the LP4 deconvolution algorithm, which reports triglyceride-rich lipoprotein particles (TRLPs), high-density lipoprotein particles (HDLPs), and low-density lipoprotein particles (LDLPs).
Results
Patients with lipodystrophy had elevated large TRLPs and smaller HDLPs and LDLPs compared with controls. Five patients with lipodystrophy had chylomicrons, compared with zero controls. Metreleptin decreased the size and concentration of TRLPs, eliminated chylomicrons in all but one patient, decreased LDLPs, and increased LDLP size. Metreleptin treatment did not have major effects on HDLPs.
Conclusions
Patients with lipodystrophy had an atherogenic lipoprotein profile at baseline consistent with elevated CVD risk, which improved after metreleptin treatment. The presence of fasting chylomicrons in a subset of patients with lipodystrophy suggests saturation of chylomicron clearance by lipoprotein lipase.
Oxford University Press